Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at B.Riley/FBR
Tweet
Share
E-mailGet Alerts SNDX Hot Sheet
Price: $19.79 +2.43%
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 11 | New: 23
Join SI Premium – FREE
B.Riley/FBR analyst Harshita Polishetty lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $26.00 (from $40.00) while maintaining a Buy rating following 4Q report.
On the earnings call, management noted that the company has currently decided to defer the advancement of the entinostat-PD-1 combination program, which includes the previously announced ENCORE 607 registration trial in non-small cell lung cancer (NSCLC).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Take-Two Interactive (TTWO) PT Raised to $368 at BofA Securities
- Norwegian Cruise (NCLH) PT Raised to $24 at TD Cowen
- Public Storage (PSA) PT Raised to $338 at Truist Securities
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
